Literature DB >> 10163569

Interferon-alpha in hepatitis C. Dosage, costs and benefits.

A Briggs1, A Shiell.   

Abstract

Mesh：

Substances：

Year:  1996        PMID： 10163569     DOI： 10.2165/00019053-199610030-00002

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  28 in total

1.  Interferon and chronic non-A, non-B hepatitis: whom are we treating?

Authors:  R L Koretz
Journal:  Hepatology       Date:  1990-09       Impact factor: 17.425

2.  Long-term follow-up of patients with chronic hepatitis C treated with different doses of interferon-alpha 2b.

Authors:  G Saracco; F Rosina; M L Abate; L Chiandussi; V Gallo; E Cerutti; A Di Napoli; A Solinas; A Deplano; A Tocco
Journal:  Hepatology       Date:  1993-12       Impact factor: 17.425

Review 3.  Hepatitis C virus in the setting of transplantation.

Authors:  N A Terrault; T L Wright
Journal:  Semin Liver Dis       Date:  1995-02       Impact factor: 6.115

4.  The cost effectiveness of alpha interferon in the treatment of chronic active hepatitis C.

Authors:  A Shiell; A Briggs; G C Farrell
Journal:  Med J Aust       Date:  1994-03-07       Impact factor: 7.738

5.  Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial.

Authors:  G L Davis; L A Balart; E R Schiff; K Lindsay; H C Bodenheimer; R P Perrillo; W Carey; I M Jacobson; J Payne; J L Dienstag
Journal:  N Engl J Med       Date:  1989-11-30       Impact factor: 91.245

6.  An economic evaluation of the costs of alpha-interferon treatment of chronic active hepatitis due to hepatitis B or C virus.

Authors:  J L Garcia de Ancos; J A Roberts; G M Dusheiko
Journal:  J Hepatol       Date:  1990       Impact factor: 25.083

Review 7.  Therapy of hepatitis C.

Authors:  M W Fried; J H Hoofnagle
Journal:  Semin Liver Dis       Date:  1995-02       Impact factor: 6.115

8.  A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group.

Authors:  T Poynard; P Bedossa; M Chevallier; P Mathurin; C Lemonnier; C Trepo; P Couzigou; J L Payen; M Sajus; J M Costa
Journal:  N Engl J Med       Date:  1995-06-01       Impact factor: 91.245

9.  Clinical outcomes after transfusion-associated hepatitis C.

Authors:  M J Tong; N S el-Farra; A R Reikes; R L Co
Journal:  N Engl J Med       Date:  1995-06-01       Impact factor: 91.245

10.  Treatment of chronic type B and C hepatitis with interferon alfa: an economic appraisal.

Authors:  G M Dusheiko; J A Roberts
Journal:  Hepatology       Date:  1995-12       Impact factor: 17.425
View more
  2 in total

1.  Interferon-alpha in hepatitis C.

Authors:  R S Koff
Journal:  Pharmacoeconomics       Date:  1997-05       Impact factor: 4.981

2.  Assessment of viral genotype impact to the cost-effectiveness and overall costs of care for PEG-interferon-2α + ribavirine treated chronic hepatitis C patients.

Authors:  Mihajlo Jakovljevic; Zeljko Mijailovic; Biljana Popovska Jovicic; Predrag Canovic; Olgica Gajovic; Mirjana Jovanovic; Dejan Petrovic; Olivera Milovanovic; Natasa Djordjevic
Journal:  Hepat Mon       Date:  2013-06-19       Impact factor: 0.660
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.